Pharmaceuticals, Biotechnology and Life Sciences
Euronext-listed Genticel and a privately-held Swiss GenKyoTex biopharmaceutical companies, will come together to become Genkyotex, a listed Franco-Swiss company whose focus will be develping a a pipeline of NOX inhibitors, a new therapeutic class in fibrosis and inflammatory pain.
Onxeo, an oncology French-based focused drugmaker and a cancer researcher, the Institut Curie, have kicked off several cancer studies, to test the combination of radiotherapy, DNA repair inhibitors and immunotherapy.
Cellectis’s scinetists lead by Dr Alexandre Juillerat have designed a new CAR architecture that contains an integrated microenvironment sensor. Their work was recently published in a scientific magazine “Scientific Reports”.
For the last year, Sanofi’s chief executive has made clear his quest for deals to help revive the fortunes of France’s biggest drugmaker.
The market is still waiting. Olivier Brandicourt’s failure to land two big biotech acquisitions he was chasing has led to growing impatience among some investors.
Pharnext, a French biopharmaceutical company focused on drugs against neurodegenerative diseases, has been named Best Life-Sciences IPO France 2016 Award.
French drugmaker Ipsen said on Monday that Claude Bertrand, Executive Vice President, R&D, Chief Scientific Officer, will step down in January…
The U.S. Food and Drug Administration (FDA) has granted “Fast Track” status to French biopharmaceutical company Neovacs’s IFNalpha Kinoid in…
GeNeuro and Servierhave set up a study they named ANGEL-MS, which is a long-term extension study for patients with multiple sclerosis…
By Pamela Barbaglia, Olivia Oran and Arno Schuetze LONDON/NEW YORK/FRANKFURT (Reuters) – Investment bank Lazard is working with Sanofi’s management…